Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in Relapsed or Refractory T-Cell Lymphoma
NCT00798096Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Mar 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of fostamatinib in T-cell lymphoma, sponsored by Rigel Pharmaceuticals, Inc.. Started Mar 2009; status: completed.
02
Drugs
fostamatinib
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT00798096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00798096.